February 2, 2017 Bio/Pharma/CRO M&A, Partnerships

Arven Pharmaceuticals selects GE Healthcare’s FlexFactory to improve Turkish and regional access to biopharmaceuticals

CHALFONT ST. GILES, UK and ISTANBUL, TURKEY– 2 February 2017 – Arven Pharmaceuticals, a Toksoz Group Company, has selected GE Healthcare’s FlexFactory manufacturing platform to expand production capacity at its facility in Kirklareli, Turkey. With this expanded capacity, Arven will support local healthcare needs by bringing biopharmaceuticals to the Turkish and surrounding markets faster, whilst... Read more

January 30, 2017 Bio/Pharma/CRO Clinical Research/Diagn.

Announcement on submission of the Clinical Trial Plan Notification for phase II clinical trial of Oncolytic virus HF10 in Japan

2017 2017/01/30 Announcement on submission of the Clinical Trial Plan Notification for phase II clinical trial of Oncolytic virus HF10 in Japan Kusatsu/Shiga, Japan — January 30, 2017 — Takara Bio Inc. (Takara Bio), today announced that the Clinical Trial Notification was submitted to PMDA (Pharmaceuticals and Medical Devices Agency; Japanese regulatory agency) to conduct... Read more

January 29, 2017 Bio/Pharma/CRO Lab Top-10 Life Science Tools M&A, Partnerships

10x Genomics Collaborates with PerkinElmer to Jointly Offer Automated Next Generation Sequencing Solutions to Researchers

Combines award-winning Chromium™ System from 10x Genomics with PerkinElmer’s state-of-the-art automation solutions PLEASANTON, Calif., January 9, 2017 – 10x Genomics, Inc., a company focused on enabling the mastery of biology by accelerating genomic discovery, today announced they and PerkinElmer, Inc. will jointly offer automated next-generation sequencing (NGS) solutions. PerkinElmer’s automation solutions increase both the throughput... Read more

January 24, 2017 Bio/Pharma/CRO Clinical Research/Diagn.

Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of NY-ESO-1・siTCR gene therapy in Japan

2017 2017/01/24 Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of NY-ESO-1・siTCR gene therapy in Japan Kusatsu/Shiga, Japan — January 24, 2017 — Takara Bio Inc. (Takara Bio), today announced that it has submitted the Clinical Trial Notification for regenerative medicines to PMDA (Pharmaceuticals and Medical Devices Agency), Japanese... Read more

January 11, 2017 Bio/Pharma/CRO Clinical Research/Diagn.

Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of CAR gene therapy in Japan

2017 2017/01/11 Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of CAR gene therapy in Japan Kusatsu/Shiga, Japan — January 11, 2017 —Takara Bio Inc. (Takara Bio), today announced that it has submitted the Clinical Trial Notification for regenerative medicines to PMDA (Pharmaceuticals and Medical Devices Agency), Japanese regulatory... Read more

November 15, 2016 Bio/Pharma/CRO Licensing, IP, and Legal M&A, Partnerships Product Launch

UC San Francisco and GE Healthcare Launch Deep Learning Partnership to Advance Care Globally

UC San Francisco’s Center for Digital Health Innovation and GE Healthcare today announced a partnership to develop a library of deep learning algorithms – complex problem-solving formulas – that will empower clinicians to make faster and more effective decisions about the diagnosis and management of patients with some of the most common and complex medical... Read more

November 13, 2016 Bio/Pharma/CRO Life Science Tools Product Launch

QIAGEN Introduces Novel Technology for Customized RNAi Assay Products

VENLO, The Netherlands, November 13 /PRNewswire-FirstCall/ -- - Worldwide First Solution for Flexible siRNA Selection Provides New Dimension of Utility and Performance in one of Life Sciences' Most Promising Disciplines QIAGEN, (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) the world's leading provider of products for pre-analytical sample preparation and a leader in molecular diagnostics, has introduced... Read more

November 1, 2016 Bio/Pharma/CRO Cell Analysis Tools M&A, Partnerships Product Launch

GE Healthcare and Valneva Collaboration Delivers Optimized Cell Culture Medium for Vaccine Production

Chalfont St. Giles, UK and Lyon, France – 2 November, 2016 – GE Healthcare’s Life Sciences business and Valneva SE, a fully integrated vaccine biotech company, are sharing the results of a successful collaboration to optimize virus productivity in Valneva’s EB66® cell-line, a proprietary technology for the production of a wide variety of vaccines, including... Read more